Related Experiment Video
Updated: Mar 30, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder
Yong-Tong Zhu1,2, Shi-Yu Pang3, Cheng-Yong Lei4
1Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China. zhuyongtong@sina.com.
Introduction:
In previous study the streptavidin interleukin-2 (SA-IL-2)-modified MB49 vaccine was effective against bladder cancer in a mouse model. However, a small portion of tumors regrew because the vaccine could not eliminate MB49 bladder cancer stem cells (MCSCs). Accordingly, we developed a SA-IL-2-modified MCSCs vaccine and evaluated its antitumor effects.
Methods:
MCSCs were isolated and identified in cancer stem cells (CSCs) characters, with high expression of CSCs markers, higher resistance to chemotherapy, greater migration in vitro, and stronger tumorigenicity in vivo. The SA-IL-2 MCSCs vaccine was prepared and its bioactivity was evaluated. The protective, therapeutic, specific and memory immune response in animal experiments were designed to identify whether the vaccine elicited antitumor immunity and acted against metastatic bladder cancer.
Results:
MCSCs had higher level of CD133 and CD44, less susceptibility to chemotherapy, more pronounced migration and greater tumorigenic ability. The successfully prepared SA-IL-2 MCSCs vaccine inhibited the tumor volume and prolonged mice survival in animal experiments. The expression of IgG, the population of dendritic cells, CD8(+) and CD4(+) T cells were highest in the experimental group than in the four control groups.
Conclusions:
The SA-IL-2 MCSCs vaccine induced an antitumor immune response and was used to eliminate MCSCs to prevent tumor regrowth.
Insights
A novel streptavidin interleukin-2 (SA-IL-2)-modified cancer stem cell vaccine effectively targets bladder cancer. This new vaccine eliminates cancer stem cells, preventing tumor regrowth and enhancing immune response in mice.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Previous streptavidin interleukin-2 (SA-IL-2)-modified MB49 vaccines showed efficacy against bladder cancer but failed to eliminate cancer stem cells, leading to tumor regrowth.
- MB49 bladder cancer stem cells (MCSCs) exhibit characteristics of cancer stem cells (CSCs), including high marker expression, chemotherapy resistance, enhanced migration, and increased tumorigenicity.
Purpose of the Study:
- To develop and evaluate the antitumor effects of a novel SA-IL-2-modified MCSCs vaccine.
- To assess the vaccine's ability to elicit protective, therapeutic, specific, and memory immune responses against metastatic bladder cancer.
Main Methods:
- Isolation and characterization of MCSCs based on CSCs markers, chemotherapy resistance, migration, and tumorigenicity.
- Preparation and bioactivity assessment of the SA-IL-2 MCSCs vaccine.
- Evaluation of antitumor immunity through animal experiments assessing immune responses (IgG, dendritic cells, CD8(+) and CD4(+) T cells).
Main Results:
- MCSCs demonstrated elevated CD133 and CD44 levels, reduced chemotherapy susceptibility, increased migration, and higher tumorigenic potential.
- The SA-IL-2 MCSCs vaccine significantly inhibited tumor volume and prolonged survival in mice.
- Vaccine administration led to increased expression of IgG, dendritic cells, CD8(+) T cells, and CD4(+) T cells compared to control groups.
Conclusions:
- The SA-IL-2 MCSCs vaccine successfully induces an antitumor immune response.
- This vaccine effectively eliminates MCSCs, thereby preventing tumor regrowth in bladder cancer models.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...